Danaher Corporation (DHR)

Currency in USD
194.98
-1.19(-0.61%)
Closed·
194.980.00(0.00%)
·
DHR is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
192.62198.58
52 wk Range
160.93242.80
Key Statistics
Prev. Close
196.17
Open
197.49
Day's Range
192.62-198.58
52 wk Range
160.93-242.8
Volume
3.16M
Average Volume (3m)
5.21M
1-Year Change
-1.1057%
Book Value / Share
74.29
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
DHR Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
227.96
Upside
+16.91%
Members' Sentiments
Bearish
Bullish
ProTips
Has raised its dividend for 8 consecutive years

Danaher Corporation News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Analyst Ratings

22 Buy
4 Hold
0 Sell
Ratings:
26 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 227.96
(+16.91% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Morgan Stanley
Buy220.00+12.83%255.00MaintainJul 22, 2026
BofA Securities
Buy230.00+17.96%270.00MaintainJul 22, 2026
TD Cowen
Buy236.00+21.04%240.00MaintainJul 22, 2026
Deutsche Bank
Buy240.00+23.09%250.00MaintainJul 22, 2026
Stifel
Buy220.00+12.83%260.00MaintainJul 22, 2026

Danaher Corporation SWOT Analysis


Life Sciences Leade
Danaher Corporation, a $150B market cap giant, dominates life sciences, diagnostics, and CROs sectors with robust financial health and strategic market positioning
Financial Trajectory
Analysts project steady growth for Danaher, with revenue expected to reach $27.67B by 2027 and EPS rising to $9.56, showcasing strong financial outlook
Strategic Evolution
Explore Danaher's proactive cost-saving measures and operational efficiencies, aimed at expanding margins into the mid-30s and enhancing shareholder value
Market Dynamics
Average analyst price target of $284, reflecting varied perspectives on Danaher's growth potential amid biotech recovery and ongoing challenges in China
Read full SWOT analysis

Danaher Corporation Earnings Call Summary for Q2/2026

  • Danaher Q2 2026 EPS of $1.94 beat estimates by 6%, revenue of $6.3B topped forecasts by 3.3%; shares plunged 14.87% in premarket trading.
  • Core revenue grew 3% YoY, 4.5% excluding respiratory; life sciences posted strongest quarter in years, but $100M+ bioprocessing revenue shifted to 2027.
  • Full-year adjusted EPS guidance raised to $8.45-$8.60 from $8.35-$8.55, implying nearly 10% growth; core revenue outlook held at 3-4% for 2026.
  • Q3 revenue growth expected at 2-3% with 250bps respiratory headwind; core growth ex-respiratory forecast at 5%, accelerating from Q2's 4.5%.
  • Masimo acquisition closed early, immediately accretive to EPS; company expects to exit 2026 at mid-single-digit core growth as respiratory drag fades.
Last Updated: 21/07/2026, 14:12
Read Full Transcript

Earnings

Latest Release
Jul 21, 2026
EPS / Forecast
1.94 / 1.83
Revenue / Forecast
6.3B / 6.1B
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 5.61%
Dividend Yield
0.81%
Industry Median 1.53%
Annualised payout
1.60
Paid quarterly
5-Years Growth
+13.05%
Growth Streak

DHR Income Statement

Compare DHR to Peers and Sector

Metrics to compare
DHR
Peers
Sector
Relationship
P/E Ratio
34.6x24.5x−0.3x
PEG Ratio
1.76−0.320.00
Price/Book
2.6x2.1x2.6x
Price / LTM Sales
5.5x3.0x3.0x
Upside (Analyst Target)
18.0%0.0%56.6%
Fair Value Upside
Unlock2.9%10.2%Unlock

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians’ offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
310.24M44.13%60.96B
Other Institutional Investors
280.22M39.86%55.06B
Public Companies & Retail Investors
112.52M16.01%22.11B
Total
702.99M100.00%138.13B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
BlackRock, Inc.7.35%51,640,61910,146,865
Vanguard Capital Management, LLC5.85%41,127,8108,081,203

People Also Watch

111.23
NOW
+1.05%
316.16
INTU
+0.21%
1,214.83
SNDK
-5.09%
105.70
ABT
+0.09%

FAQ

What Is the Danaher (DHR) Stock Price Today?

The Danaher stock price today is 194.98 USD.

What Stock Exchange Does Danaher Trade On?

Danaher is listed and trades on the New York Stock Exchange.

What Is the Stock Symbol for Danaher?

The stock symbol for Danaher is "DHR."

What Is the Danaher Market Cap?

As of today, Danaher market cap is 137.90B USD.

What Is Danaher's Earnings Per Share (TTM)?

The Danaher EPS (TTM) is 5.61.

When Is the Next Danaher Earnings Date?

Danaher will release its next earnings report on Oct 27, 2026.

From a Technical Analysis Perspective, Is DHR a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Danaher Stock Split?

Danaher has split 5 times.

How Many Employees Does Danaher Have?

Danaher has 59000 employees.

What is the current trading status of Danaher (DHR)?

As of Jul 31, 2026, Danaher (DHR) is trading at a price of 194.98 USD, with a previous close of 196.17 USD. The stock has fluctuated within a day range of 192.62 USD to 198.58 USD, while its 52-week range spans from 160.93 USD to 242.80 USD.

What Is Danaher (DHR) Price Target According to Analysts?

The average 12-month price target for Danaher is 227.96 USD, with a high estimate of 310 USD and a low estimate of 195 USD. 22 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +16.91% Upside potential.

What Is the DHR Premarket Price?

DHR's last pre-market stock price is 197.45 USD. The pre-market share volume is 2,460.00, and the stock has decreased by 1.28, or 0.65%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.